Literature DB >> 24035971

Constitutional 11q14-q22 chromosome deletion syndrome in a child with neuroblastoma MYCN single copy.

Annalisa Passariello1, Daniele De Brasi, Raffaella Defferrari, Rita Genesio, Maria Tufano, Katia Mazzocco, Maria Capasso, Roberta Migliorati, Tommy Martinsson, Paolo Siani, Lucio Nitsch, Gian Paolo Tonini.   

Abstract

Constitutional 11q deletion is a chromosome imbalance possibly found in MCA/MR patients analyzed for chromosomal anomalies. Its role in determining the phenotype depends on extension and position of deleted region. Loss of heterozygosity of 11q (region 11q23) is also associated with neuroblastoma, the most frequent extra cranial cancer in children. It represents one of the most frequent cytogenetic abnormalities observed in the tumor of patients with high-risk disease even if germline deletion of 11q in neuroblastoma is rare. Hereby, we describe a 18 months old girl presenting with trigonocephaly and dysmorphic facial features, including hypotelorism, broad depressed nasal bridge, micrognathia, synophrys, epicanthal folds, and with a stage 4 neuroblastoma without MYCN amplification, carrying a germline 11q deletion (11q14.1-q22.3), outside from Jacobsen syndrome and from neuroblastoma 11q critical regions. The role of 11q deletion in determining the clinical phenotype and its association with neuroblastoma development in the patient are discussed.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  (123)MIBG; 11q syndrome; 123-iodine metaidobenzoguadinyl scintigrafy; ARSH, ARSE, ARSD; CNVs; CR; DCN1; DCUN1D5; DECIPHER; DGV; ECARUCA; European cytogeneticists association register of unbalanced chromosome aberrations; FISH; GYG2; INSS; International NB Staging System; MCA/MR; MLPA; MMP13; MMPs; MYCN; NB; Neuroblastoma; Oncogene; PAR1; SLE; aCGH; arilsulphatases genes; array comparative genomic hybridization; critical region; database of chromosomal imbalance and phenotype in humans using ensembl resources; database of genomic variants; defective in cullin neddylation 1; domain containing 5; fluorescence in situ hybridization; glycogenin 2 gene; matrix metalloproteinase 13; matrix metalloproteinase genes; multiple congenital anomaly/mental retardation; multiplex ligation-dependent probe amplification; neuroblastoma; pseudo autosomal region 1; structural copy number variations; systemic lupus erythematosus

Mesh:

Substances:

Year:  2013        PMID: 24035971     DOI: 10.1016/j.ejmg.2013.08.005

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  5 in total

1.  Constitutional 3p26.3 terminal microdeletion in an adolescent with neuroblastoma.

Authors:  Annalisa Pezzolo; Angela Rita Sementa; Margherita Lerone; Martina Morini; Marzia Ognibene; Raffaella Defferrari; Katia Mazzocco; Massimo Conte; Anna Rita Gigliotti; Alberto Garaventa; Vito Pistoia; Luigi Varesio
Journal:  Cancer Biol Ther       Date:  2017-04-12       Impact factor: 4.742

2.  Germline 16p11.2 Microdeletion Predisposes to Neuroblastoma.

Authors:  Laura E Egolf; Zalman Vaksman; Gonzalo Lopez; Jo Lynne Rokita; Apexa Modi; Patricia V Basta; Hakon Hakonarson; Andrew F Olshan; Sharon J Diskin
Journal:  Am J Hum Genet       Date:  2019-08-29       Impact factor: 11.025

Review 3.  Genetic advances in craniosynostosis.

Authors:  Wanda Lattanzi; Marta Barba; Lorena Di Pietro; Simeon A Boyadjiev
Journal:  Am J Med Genet A       Date:  2017-02-04       Impact factor: 2.802

Review 4.  Genetic susceptibility to neuroblastoma: current knowledge and future directions.

Authors:  Laura E Ritenour; Michael P Randall; Kristopher R Bosse; Sharon J Diskin
Journal:  Cell Tissue Res       Date:  2018-03-27       Impact factor: 5.249

Review 5.  11q deletion in neuroblastoma: a review of biological and clinical implications.

Authors:  Vid Mlakar; Simona Jurkovic Mlakar; Gonzalo Lopez; John M Maris; Marc Ansari; Fabienne Gumy-Pause
Journal:  Mol Cancer       Date:  2017-06-29       Impact factor: 27.401

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.